Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.

Go RS, Gundrum JD, Neuner JM.

Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):177-186.e4. doi: 10.1016/j.clml.2014.09.004. Epub 2014 Sep 28.

2.

Curing myeloma at last: defining criteria and providing the evidence.

Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J.

Blood. 2014 Nov 13;124(20):3043-51. doi: 10.1182/blood-2014-07-552059. Epub 2014 Oct 7.

3.

Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma.

Isoda A, Kaira K, Iwashina M, Oriuchi N, Tominaga H, Nagamori S, Kanai Y, Oyama T, Asao T, Matsumoto M, Sawamura M.

Cancer Sci. 2014 Nov;105(11):1496-502. doi: 10.1111/cas.12529. Epub 2014 Oct 9.

4.

The future of autologous stem cell transplantation in myeloma.

van Rhee F, Giralt S, Barlogie B.

Blood. 2014 Jul 17;124(3):328-33. doi: 10.1182/blood-2014-03-561985. Epub 2014 Jun 3. Review.

5.

Association of response endpoints with survival outcomes in multiple myeloma.

Lonial S, Anderson KC.

Leukemia. 2014 Feb;28(2):258-68. doi: 10.1038/leu.2013.220. Epub 2013 Jul 19. Review.

6.

Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.

Pessoa de Magalhães RJ, Vidriales MB, Paiva B, Fernandez-Gimenez C, García-Sanz R, Mateos MV, Gutierrez NC, Lecrevisse Q, Blanco JF, Hernández J, de las Heras N, Martinez-Lopez J, Roig M, Costa ES, Ocio EM, Perez-Andres M, Maiolino A, Nucci M, De La Rubia J, Lahuerta JJ, San-Miguel JF, Orfao A; Spanish Myeloma Group (GEM); Grupo Castellano-Leones de Gammapatias Monoclonales, cooperative study groups.

Haematologica. 2013 Jan;98(1):79-86. doi: 10.3324/haematol.2012.067272. Epub 2012 Jul 6.

7.

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.

Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, San Miguel J, Lonial S; International Myeloma Working Group.

Blood. 2011 Jun 9;117(23):6063-73. doi: 10.1182/blood-2011-02-297325. Epub 2011 Mar 29.

8.

Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.

Weiss BM, Kuehl WM.

Expert Rev Hematol. 2010 Apr;3(2):165-74. doi: 10.1586/ehm.10.13. Review.

9.

Current multiple myeloma treatment strategies with novel agents: a European perspective.

Ludwig H, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Zweegman S.

Oncologist. 2010;15(1):6-25. doi: 10.1634/theoncologist.2009-0203. Epub 2010 Jan 19. Review.

10.

Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations.

Bladé J, Dimopoulos M, Rosiñol L, Rajkumar SV, Kyle RA.

J Clin Oncol. 2010 Feb 1;28(4):690-7. doi: 10.1200/JCO.2009.22.2257. Epub 2009 Dec 21. Review.

11.

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, Short KE, Stewart AK, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Bergsagel PL.

Mayo Clin Proc. 2009 Dec;84(12):1095-110. doi: 10.4065/mcp.2009.0603.

12.

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.

Hoering A, Crowley J, Shaughnessy JD Jr, Hollmig K, Alsayed Y, Szymonifka J, Waheed S, Nair B, van Rhee F, Anaissie E, Barlogie B.

Blood. 2009 Aug 13;114(7):1299-305. doi: 10.1182/blood-2009-03-211953. Epub 2009 Jun 10.

13.

A monoclonal gammopathy precedes multiple myeloma in most patients.

Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM.

Blood. 2009 May 28;113(22):5418-22. doi: 10.1182/blood-2008-12-195008. Epub 2009 Feb 20.

14.

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.

Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, Alsayed Y, Waheed S, Petty N, Epstein J, Shaughnessy JD Jr, Tricot G, Zangari M, Zeldis J, Barer S, Crowley J.

Blood. 2008 Oct 15;112(8):3115-21. doi: 10.1182/blood-2008-03-145235. Epub 2008 May 20.

15.

The Arkansas approach to therapy of patients with multiple myeloma.

Barlogie B, Anaissie E, van Rhee F, Pineda-Roman M, Zangari M, Shaughnessy J, Epstein J, Crowley J.

Best Pract Res Clin Haematol. 2007 Dec;20(4):761-81. Review.

16.

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.

van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy JD Jr, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B.

Blood. 2007 Aug 1;110(3):827-32. Epub 2007 Apr 6.

Supplemental Content

Support Center